{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:27:22Z","timestamp":1736227642736,"version":"3.32.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lfs.2024.123144","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T05:46:53Z","timestamp":1729144013000},"page":"123144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term therapeutic efficacy and safety profiles of hpCas13d RNA editing in treating early-onset hypertrophic cardiomyopathy"],"prefix":"10.1016","volume":"358","author":[{"given":"Yingmei","family":"Lou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhizhao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilong","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juntao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianpin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lfs.2024.123144_bb0005","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","article-title":"Molecular genetic basis of hypertrophic cardiomyopathy","volume":"128","author":"Marian","year":"2021","journal-title":"Circ. Res."},{"issue":"10316","key":"10.1016\/j.lfs.2024.123144_bb0010","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/S0140-6736(21)01205-8","article-title":"Hypertrophic cardiomyopathy: a practical approach to guideline directed management","volume":"398","author":"Ommen","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.lfs.2024.123144_bb0015","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy","volume":"107","author":"Richard","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.lfs.2024.123144_bb0020","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/gim.2014.205","article-title":"Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity","volume":"17","author":"Alfares","year":"2015","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.lfs.2024.123144_bb0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/CIRCRESAHA.110.223842","article-title":"Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor","volume":"111","author":"Moore","year":"2012","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.lfs.2024.123144_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/CIRCRESAHA.115.303178","article-title":"betA-myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations","volume":"115","author":"Blankenburg","year":"2014","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.lfs.2024.123144_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2005.033886","article-title":"Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling","volume":"42","author":"Ingles","year":"2005","journal-title":"J. Med. Genet."},{"issue":"22","key":"10.1016\/j.lfs.2024.123144_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10225256","article-title":"Compound mutation in cardiac sarcomere proteins is associated with increased risk for major arrhythmic events in pediatric onset hypertrophic cardiomyopathy","volume":"10","author":"Pollmann","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2024.123144_bb0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev-med-042220-021539","article-title":"Hypertrophic cardiomyopathy: new concepts and therapies","volume":"73","author":"Maron","year":"2022","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.lfs.2024.123144_bb0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.17925\/HI.2022.16.2.91","article-title":"Mavacamten: a first-in-class oral modulator of cardiac myosin for the treatment of symptomatic hypertrophic obstructive cardiomyopathy","volume":"16","author":"Reyes","year":"2022","journal-title":"Heart Int."},{"key":"10.1016\/j.lfs.2024.123144_bb0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-med-052422-020535","article-title":"Genetics of dilated cardiomyopathy","author":"Eldemire","year":"2024","journal-title":"Annu. Rev. Med."},{"issue":"21","key":"10.1016\/j.lfs.2024.123144_bb0060","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1161\/CIRCULATIONAHA.123.065017","article-title":"Improved cardiac performance and decreased arrhythmia in hypertrophic cardiomyopathy with non-\u03b2-blocking R-enantiomer carvedilol","volume":"148","author":"Seo","year":"2023","journal-title":"Circulation"},{"issue":"10293","key":"10.1016\/j.lfs.2024.123144_bb0065","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"issue":"6154","key":"10.1016\/j.lfs.2024.123144_bb0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.lfs.2024.123144_bb0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1161\/CIRCULATIONAHA.123.067890","article-title":"Allele-specific suppression of variant MHC with high-precision RNA nuclease CRISPR-Cas13d prevents hypertrophic cardiomyopathy","author":"Yang","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lfs.2024.123144_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13059-023-02860-w","article-title":"The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model","volume":"24","author":"Li","year":"2023","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.lfs.2024.123144_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111226","article-title":"Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells","volume":"40","author":"Kelley","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.lfs.2024.123144_bb0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41587-022-01419-7","article-title":"High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects","volume":"41","author":"Tong","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.lfs.2024.123144_bb0095","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"12","key":"10.1016\/j.lfs.2024.123144_bb0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.lfs.2024.123144_bb0105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.lfs.2024.123144_bb0110","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/CIRCULATIONAHA.120.050812","article-title":"LARP7 protects against heart failure by enhancing mitochondrial biogenesis","volume":"143","author":"Yu","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.lfs.2024.123144_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Hum. Gene. Ther. Clin. Dev."},{"issue":"7","key":"10.1016\/j.lfs.2024.123144_bb0120","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.lfs.2024.123144_bb0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.lfs.2024.123144_bb0130","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cell.2020.03.024","article-title":"Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice","volume":"181","author":"Zhou","year":"2020","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.lfs.2024.123144_bb0135","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1161\/CIRCULATIONAHA.121.053575","article-title":"Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy","volume":"144","author":"Ranjbarvaziri","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lfs.2024.123144_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00392-017-1155-5","article-title":"Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals","volume":"107","author":"Sedaghat-Hamedani","year":"2018","journal-title":"Clin. Res. Cardiol."},{"issue":"12","key":"10.1016\/j.lfs.2024.123144_bb0145","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1161\/01.CIR.91.12.2911","article-title":"A myosin missense mutation, not a null allele, causes familial hypertrophic cardiomyopathy","volume":"91","author":"Nishi","year":"1995","journal-title":"Circulation"},{"issue":"44","key":"10.1016\/j.lfs.2024.123144_bb0150","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.lfs.2024.123144_bb0155","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.lfs.2024.123144_bb0160","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40256-023-00599-0","article-title":"Aficamten: a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy","volume":"23","author":"Sebastian","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"2","key":"10.1016\/j.lfs.2024.123144_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.lfs.2024.123144_bb0175","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/nar\/gki312","article-title":"A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites","volume":"33","author":"Du","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"7109","key":"10.1016\/j.lfs.2024.123144_bb0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature05179","article-title":"Prevalence of off-target effects in RNA interference screens","volume":"443","author":"Ma","year":"2006","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lfs.2024.123144_bb0185","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41587-022-01595-6","article-title":"Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase","volume":"41","author":"Tong","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.lfs.2024.123144_bb0190","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","article-title":"Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity","volume":"41","author":"Neugebauer","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.lfs.2024.123144_bb0195","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2024.123144_bb0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41422-024-00930-7","article-title":"Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice","author":"Wu","year":"2024","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.lfs.2024.123144_bb0205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2018.02.028","article-title":"Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein","volume":"70","author":"Yan","year":"2018","journal-title":"Mol. Cell"},{"issue":"7092","key":"10.1016\/j.lfs.2024.123144_bb0210","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.lfs.2024.123144_bb0215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.lfs.2024.123144_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.lfs.2024.123144_bb0225","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nbt856","article-title":"Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors","volume":"21","author":"Muller","year":"2003","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123144_bb0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1525-0016(03)00123-0","article-title":"In vitro selection of viral vectors with modified tropism: the adeno-associated virus display","volume":"8","author":"Perabo","year":"2003","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.lfs.2024.123144_bb0235","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1016\/j.ymthe.2022.07.003","article-title":"AAV capsid engineering identified two novel variants with improved in vivo tropism for cardiomyocytes","volume":"30","author":"Rode","year":"2022","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.lfs.2024.123144_bb0240","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1152\/physiolgenomics.00032.2022","article-title":"Distribution of cardiomyocyte-selective adeno-associated virus serotype 9 vectors in swine following intracoronary and intravenous infusion","volume":"54","author":"Li","year":"2022","journal-title":"Physiol. Genomics"},{"issue":"1","key":"10.1016\/j.lfs.2024.123144_bb0245","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41598-024-51712-5","article-title":"Caridac vein retroinjections provide an efficient approach for global left ventricular gene transfer with adenovirus and adeno-associated virus","volume":"14","author":"Lampela","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.lfs.2024.123144_bb0250","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ymthe.2024.05.004","article-title":"Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer","volume":"32","author":"Smith","year":"2024","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.lfs.2024.123144_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.lfs.2024.123144_bb0260","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1038\/s41467-019-10555-9","article-title":"Beta-cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity","volume":"10","author":"Adhikari","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.lfs.2024.123144_bb0265","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1073\/pnas.92.9.3864","article-title":"Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy","volume":"92","author":"Rayment","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.lfs.2024.123144_bb0270","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41591-019-0500-9","article-title":"Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss","volume":"25","author":"Gyorgy","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2024.123144_bb0275","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omtn.2019.02.019","article-title":"Allele-specific CRISPR\/Cas9 correction of a heterozygous DNM2 mutation rescues centronuclear myopathy cell phenotypes","volume":"16","author":"Rabai","year":"2019","journal-title":"Mol Ther Nucleic Acids."},{"issue":"10","key":"10.1016\/j.lfs.2024.123144_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110475","article-title":"Mutant CHCHD10 causes an extensive metabolic rewiring that precedes OXPHOS dysfunction in a murine model of mitochondrial cardiomyopathy","volume":"38","author":"Sayles","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.lfs.2024.123144_bb0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington\u2019s disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.lfs.2024.123144_bb0290","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.molcel.2018.09.018","article-title":"CRISPR-based technologies: impact of RNA-targeting systems","volume":"72","author":"Terns","year":"2018","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.lfs.2024.123144_bb0295","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41589-024-01593-6","article-title":"Structures, mechanisms and applications of RNA-centric CRISPR-Cas13","volume":"20","author":"Yang","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"21","key":"10.1016\/j.lfs.2024.123144_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/cells11213511","article-title":"Mitochondrial cardiomyopathy: molecular epidemiology, diagnosis, models, and therapeutic management","volume":"11","author":"Yang","year":"2022","journal-title":"Cells"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524007343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524007343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:38:19Z","timestamp":1736185099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524007343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":59,"alternative-id":["S0024320524007343"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123144","relation":{},"ISSN":["0024-3205"],"issn-type":[{"type":"print","value":"0024-3205"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term therapeutic efficacy and safety profiles of hpCas13d RNA editing in treating early-onset hypertrophic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Shanghai Jiaotong University. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"123144"}}